Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
The purpose of this study is to assess the safety and effectiveness of the investigational drug repotrectinib in children and young adults with solid tumors that have continued to grow or spread despite treatment. Repotrectinib works by targeting and blocking certain proteins that play a role in cancer growth. Some of these proteins are controlled by the ALK, ROS1, NTRK1, NTRK2, and NTRK3 genes. Researchers also think that combining repotrectinib with the chemotherapy drugs irinotecan and temozolomide may make the treatment more effective.
The purpose of this study is to establish a registry to learn about neurocutaneous melanocytosis (NCM) and how people respond to treatments for this rare disease. NCM is seen mainly in children born with large dark-colored areas of skin called cutaneous melanocytic nevi (LCMN). About one in four of children with LCMN also develop NCM.
Teclistamab is given as an injection under the skin. The goal is to see if lower doses or stopping treatment will have the same benefit with fewer side effects.
The purpose of this study is to find the highest dose of the investigational drug XMT-1660 that can be given safely in people with advanced triple-negative breast cancer (TNBC) that persists despite prior chemotherapy. TNBC includes breast cancers that do not contain receptors for estrogen or progesterone and do not have the HER2 protein, so they cannot be treated with medications that target those proteins.
The purpose of this study is to find the highest dose of the investigational drug ONO-4685 that can be given safely in people with cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma (PTCL) that came back or continued to grow despite treatment. ONO-4685 may strengthen the immune system's ability to fight cancer cells by activating a patient's own cells to destroy the tumor. It is given intravenously (by vein).
Skin (dermatologic) conditions are common in people who are receiving or have received cancer treatment. Sometimes the condition is related to the cancer, and sometimes it is related to cancer treatment. In either case, skin conditions can affect a person's quality of life.
Researchers want to see if disitamab vedotin plus tucatinib is safe and works well in people with advanced solid tumors. They want to find the best dose of disitamab vedotin to give with tucatinib. The people in this study have different types of HER2-positive and HER2-low solid tumors, including breast cancer.
In this study, researchers are assessing the drug asciminib for people who recently learned they have chronic myeloid leukemia (CML). They will take it twice a day. If after two years they do not respond well to asciminib, they may take the drug nilotinib with asciminib.
Radiation therapy is one of the usual approaches to treating triple-negative breast cancer (TNBC). Researchers think that adding the immunotherapy drug pembrolizumab, with or without olaparib, to radiation therapy may be a better treatment for TNBC than radiation therapy alone.
Researchers are seeking the best dose of raludotatug deruxtecan (R-DXd) for people with ovarian cancer when given with standard chemotherapy. The people in this study have ovarian cancer that came back after chemotherapy that included a platinum-containing drug.
